Literature DB >> 19372759

Regulatory role of CCN3 in melanoma cell interaction with the extracellular matrix.

Viviana Vallacchi1, Monica Rodolfo.   

Abstract

It is increasingly clear that melanoma cells modify their environment not only through the release of growth factors (GFs) and cytokines that have autocrine or paracrine effects and strongly modulate the immune response, but also by secreting proteins that become structural or transient components of the extracellular matrix (ECM). Melanoma cell secreted proteins play a significant role in cell-ECM interactions, helping tumor cells to invade neighbouring stroma, disseminate and survive in other tissue contexts. CCN3/NOV (nephroblastoma overexpressed) is a matricellular protein that belongs to the CCN family of proteins containing six members in humans. Its structure consists of modules related to functional domains previously identified in major regulatory proteins: insulin-like growth factor-binding protein (IGFBP), von Willebrand factor type C repeats (VWC), thrombospondin type 1 repeats, and secreted regulatory factors containing cysteine knot motifs. Extensive studies have indicated that the biological properties of CCN3 are dependent upon the cellular context, and its role in melanoma seems to recapitulate cell context functions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19372759      PMCID: PMC2675140          DOI: 10.4161/cam.3.1.6836

Source DB:  PubMed          Journal:  Cell Adh Migr        ISSN: 1933-6918            Impact factor:   3.405


  30 in total

1.  A molecular signature of metastasis in primary solid tumors.

Authors:  Sridhar Ramaswamy; Ken N Ross; Eric S Lander; Todd R Golub
Journal:  Nat Genet       Date:  2002-12-09       Impact factor: 38.330

Review 2.  Tenascin-C induced signaling in cancer.

Authors:  Gertraud Orend; Ruth Chiquet-Ehrismann
Journal:  Cancer Lett       Date:  2006-04-24       Impact factor: 8.679

3.  Expression of CCN3 protein in human Wilms' tumors: immunohistochemical detection of CCN3 variants using domain-specific antibodies.

Authors:  Manish Mani Subramaniam; Noureddine Lazar; Samuel Navarro; Bernard Perbal; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2007-12-08       Impact factor: 4.064

4.  Antiproliferative activity of CCN3: involvement of the C-terminal module and post-translational regulation.

Authors:  A M Bleau; N Planque; N Lazar; D Zambelli; A Ori; T Quan; G Fisher; K Scotlandi; B Perbal
Journal:  J Cell Biochem       Date:  2007-08-15       Impact factor: 4.429

Review 5.  Autocrine and paracrine regulation by cytokines and growth factors in melanoma.

Authors:  E Lázár-Molnár; H Hegyesi; S Tóth; A Falus
Journal:  Cytokine       Date:  2000-06       Impact factor: 3.861

Review 6.  CCN proteins: multifunctional signalling regulators.

Authors:  Bernard Perbal
Journal:  Lancet       Date:  2004-01-03       Impact factor: 79.321

7.  Mechanisms of hypoxic gene regulation of angiogenesis factor Cyr61 in melanoma cells.

Authors:  Manfred Kunz; Steffen Moeller; Dirk Koczan; Peter Lorenz; Roland H Wenger; Michael O Glocker; Hans-Juergen Thiesen; Gerd Gross; Saleh M Ibrahim
Journal:  J Biol Chem       Date:  2003-08-25       Impact factor: 5.157

8.  Domain-specific CCN3 antibodies as unique tools for structural and functional studies.

Authors:  Noureddine Lazar; Cristina Manara; Samuel Navarro; Anne-Marie Bleau; Antonio Llombart-Bosch; Katia Scotlandi; Nathalie Planque; Bernard Perbal
Journal:  J Cell Commun Signal       Date:  2007-09-08       Impact factor: 5.782

9.  NOV (CCN3) functions as a regulator of human hematopoietic stem or progenitor cells.

Authors:  Rajeev Gupta; Dengli Hong; Francisco Iborra; Samantha Sarno; Tariq Enver
Journal:  Science       Date:  2007-04-27       Impact factor: 47.728

10.  Downregulation of CCN3 expression as a potential mechanism for melanoma progression.

Authors:  M Fukunaga-Kalabis; G Martinez; S M Telson; Z-J Liu; K Balint; I Juhasz; D E Elder; B Perbal; M Herlyn
Journal:  Oncogene       Date:  2007-10-29       Impact factor: 8.756

View more
  6 in total

1.  CCN6 modulates BMP signaling via the Smad-independent TAK1/p38 pathway, acting to suppress metastasis of breast cancer.

Authors:  Anupama Pal; Wei Huang; Xin Li; Kathy A Toy; Zaneta Nikolovska-Coleska; Celina G Kleer
Journal:  Cancer Res       Date:  2012-07-17       Impact factor: 12.701

2.  Upregulation of intratumoral HLA class I and peritumoral Mx1 in ulcerated melanomas.

Authors:  Daniëlle Verver; Vichnou Poirier-Colame; Gorana Tomasic; Khadija Cherif-Rebai; Dirk J Grunhagen; Cornelis Verhoef; Stefan Suciu; Caroline Robert; Laurence Zitvogel; Alexander M M Eggermont
Journal:  Oncoimmunology       Date:  2019-09-06       Impact factor: 8.110

3.  Blockade of CCN6 (WISP3) activates growth factor-independent survival and resistance to anoikis in human mammary epithelial cells.

Authors:  Wei Huang; Maria E Gonzalez; Kathy A Toy; Mousumi Banerjee; Celina G Kleer
Journal:  Cancer Res       Date:  2010-04-15       Impact factor: 12.701

4.  Discovery of IL-18 as a novel secreted protein contributing to doxorubicin resistance by comparative secretome analysis of MCF-7 and MCF-7/Dox.

Authors:  Ling Yao; Yan Zhang; Keying Chen; Xiaofang Hu; Lisa X Xu
Journal:  PLoS One       Date:  2011-09-08       Impact factor: 3.240

5.  CCN3 modulates bone turnover and is a novel regulator of skeletal metastasis.

Authors:  Véronique Ouellet; Peter M Siegel
Journal:  J Cell Commun Signal       Date:  2012-03-18       Impact factor: 5.782

Review 6.  A new molecular risk pathway for postpartum mood disorders: clues from steroid sulfatase-deficient individuals.

Authors:  Harish Thippeswamy; William Davies
Journal:  Arch Womens Ment Health       Date:  2020-11-20       Impact factor: 3.633

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.